Evidence map›Paper›PMID 23088863›Full record

ReviewAdvanced drug delivery reviews2013

Advanced materials and processing for drug delivery: the past and the future.

Ying Zhang, Hon Fai Chan, Kam W Leong

Abstract readReview
In one paragraph

Review in Advanced drug delivery reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 179 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
179citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

179 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Role of Anti-GDACS applied bio materials · 2026
    Article
  10. Article
  11. Enhanced cytotoxic activity ofNanoscale advances · 2026
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

119 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ying ZhangDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Hon Fai Chan
Kam W Leong

Funding

Oral Therapy for Hemophilia AR01HL109442 · NHLBI · UNIVERSITY OF FLORIDA · PI DANIELL, HENRY, HERZOG, ROLAND W. · 2011 to 2015
$3.5M
Overcoming Immunosenescence by Nanoparticle-Mediated ActivationR01AI096305 · NIAID · DUKE UNIVERSITY · PI ABRAHAM, SOMAN N, LEONG, KAM W · 2012 to 2016
$1.8M
Oral Nonviral Gene Delivery for Hemophilla AR01HL089764 · NHLBI · DUKE UNIVERSITY · PI LEONG, KAM W · 2008 to 2011
$1.7M
Derivation of Functional Neurons from Human Adult Cells by Nonviral Gene DeliveryR21EB015300 · NIBIB · DUKE UNIVERSITY · PI LEONG, KAM W · 2012 to 2013
$421k
NHLBI NIH HHS HL089764NHLBI NIH HHS HL109442NHLBI NIH HHS R01 HL089764NHLBI NIH HHS R01 HL109442NIAID NIH HHS R01 AI096305NIBIB NIH HHS R21 EB015300
6 · The paper itself

Abstract

Design and synthesis of efficient drug delivery systems are of vital importance for medicine and healthcare. Materials innovation and nanotechnology have synergistically fueled the advancement of drug delivery. Innovation in material chemistry allows the generation of biodegradable, biocompatible, environment-responsive, and targeted delivery systems. Nanotechnology enables control over size, shape and multi-functionality of particulate drug delivery systems. In this review, we focus on the materials innovation and processing of drug delivery systems and how these advances have shaped the past and may influence the future of drug delivery.

Indexed as

Biocompatible MaterialsDrug Delivery SystemsHumansNanotechnologyPharmaceutical PreparationsBiocompatible MaterialsPharmaceutical Preparations

Identifiers

PMID23088863
PMCPMC3565095

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.